We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Taken After Miscarriage Can Predict Future Risk of Pregnancy Loss

By LabMedica International staff writers
Posted on 18 May 2023

Approximately 10% of women experience pregnancy loss, a percentage that is higher in regions where pregnancies frequently occur later in a woman's reproductive years. More...

Various factors contribute to pregnancy loss, including hormonal imbalances, endocrine disorders, clotting issues, or lifestyle-related factors. Despite the fact that one in four pregnancies results in a miscarriage, little has been done to investigate the underlying causes, with the primary focus being on the process of uterus evacuation post-miscarriage. Now, a new study has found that a post-miscarriage blood test as early as the fifth week of pregnancy could shed light on the cause and, in some instances, guide preventative treatment strategies. These findings could potentially help prevent 5% of the annual 30 million miscarriages worldwide.

In the study, a team of researchers at Hvidovre Hospital (Hvidovre, Denmark) demonstrated that a blood sample taken from the mother shortly after a miscarriage that occurred as early as the fifth week of pregnancy can identify whether there was a chromosomal abnormality in the fetus. Such tests are typically only administered after a woman has experienced multiple miscarriages and if they occurred past the tenth week of pregnancy.

This blood test can be immediately dispatched to the hospital laboratory. Here, the fetal DNA is isolated, sequenced, and analyzed for chromosomal abnormalities, which are present in approximately 50 to 60% of miscarriages. This analysis allows doctors to identify the severity of these abnormalities and estimate the risk of future miscarriages. If no abnormalities are detected, doctors can then initiate an in-depth investigation for other causes. If a cause is identified, medical professionals can assess the risks and formulate an appropriate treatment plan.

Related Links:
Hvidovre Hospital


Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.